Silexion Therapeutics’ SIL-204 shows promise in transforming pancreatic cancer treatment

Silexion Therapeutics, a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies, has released compelling preclinical data for its second-generation siRNA candidate, SIL-204. The findings reveal ... Read More